Valuation : Mymetics Corporation

Market Cap 439K 378K 355K 324K 608K 41.75M 613K 4.2M 1.64M 21.17M 1.65M 1.61M 70.1M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.1M 58.31M 53.23M 99.99M 6.86B 101M 691M 269M 3.48B 271M 265M 11.52B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-10.24%+8.79% - - 45
-1.66%-4.96%+49.84%+88.43% 68.13B
+1.58%+2.92%+46.81%+91.35% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
-1.00%-1.73%-16.15%+456.60% 26.6B
+0.01%-10.09%+0.81%-16.12% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
+0.97%+2.08%+31.42%-18.33% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+1.41%+1.25%+48.55%+146.67% 13.54B
Average -1.89%-2.71%+49.50%+186.51% 30.67B
Weighted average by Cap. -0.62%-2.34%+45.98%+147.01%

Financials

2021 2022
Net sales 430K 370K 348K 317K 596K 40.91M 600K 4.12M 1.6M 20.75M 1.61M 1.58M 68.7M 1.03M 885K 831K 759K 1.43M 97.81M 1.44M 9.85M 3.83M 49.6M 3.86M 3.78M 164M
Net income -4.73M -4.07M -3.82M -3.49M -6.56M -450M -6.6M -45.31M -17.63M -228M -17.76M -17.37M -756M -4.8M -4.14M -3.88M -3.55M -6.66M -457M -6.71M -46.03M -17.91M -232M -18.04M -17.65M -768M
Net Debt 67.1M 57.77M 54.25M 49.52M 93.03M 6.38B 93.69M 643M 250M 3.24B 252M 246M 10.72B 71.68M 61.72M 57.95M 52.9M 99.38M 6.82B 100M 687M 267M 3.46B 269M 263M 11.45B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-